archive-au.com » AU » C » CSL.COM.AU

Total: 502

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Archived ASX Releases 2008 - 2012
    financial year US dollars are the pharmaceutical industry standard currency for reporting purposes The move also reflects the increasing predominance of the Company s worldwide sales and operations in US dollars More 27 09 2012 CSL drug candidate in diabetes research breakthrough CSL Limited has developed a new drug candidate that is able to prevent the development of type 2 diabetes and reverse its progression in animal models of the disease More 11 09 2012 CSL Biotherapies awarded Pandemic Preparedness Contract by US Government CSL Biotherapies announced that it has been awarded a contract by the United States US Department of Health and Human Services to supply pre pandemic and pandemic vaccine antigens and related services to the US national stockpile More 22 08 2012 Full Year Results Announcement for 2011 12 CSL Limited ASX CSL today announced a net profit after tax of A 983 million for the twelve months ended 30 June 2012 up A 42 million or 4 5 on a reported basis when compared to the prior comparable period This result included an unfavourable foreign exchange impact of A 108 million More 03 08 2012 Successor to CEO Brian McNamee Announced CSL Limited ASX CSL CSL

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650230/page/1255930769749/PressReleaseArchive.htm (2014-01-05)
    Open archived version from archive


  • Stakeholder Engagement
    Home Corporate Responsibility Stakeholder Engagement Stakeholder Engagement We regard stakeholder engagement as a foundation of corporate responsibility and have identified our key stakeholders as patient groups employees investors regulators suppliers government healthcare professionals plasma donors business partners and the academic and scientific community Stakeholder engagement covers many different activities from the provision of information and educational material to health service providers through to active collaboration with and support of patient

    Original URL path: http://www.csl.com.au/corporate-responsibility/stakeholder-engagement.htm (2014-01-05)
    Open archived version from archive

  • Researching New Medicines
    the CEO Managing Director and is an attendee of the Board s Innovation and Development Committee The CSO is supported by the Heads of the global R D functions and the Global PharmaPlan Committee which meets regularly to review the global R D portfolio and strategic investment priorities Collaboration Our research projects are undertaken globally with research teams drawing together employees from different countries depending on their expertise We have developed a global project management framework to facilitate collaboration across national and cultural boundaries and to harness the strength of our diversity We establish strategic partnerships with academic and other organisations globally to complement our in house expertise These collaborative partnerships support a range of programs including early stage research and later stage development in plasma therapies vaccines and recombinant products A range of advisers provide additional strategic insights into our product development initiatives We enter into collaborative agreements with third parties to further the science and prospects for successful product development These partnerships often result in shared knowledge intellectual property or products The collaboration agreements address issues such as research funding payment of milestones achieved and royalties Where possible we undertake activities at our laboratories and those of our

    Original URL path: http://www.csl.com.au/corporate-responsibility/new-med-research.htm (2014-01-05)
    Open archived version from archive

  • Safety and Quality
    Good Manufacturing Practices cGMP current Good Distribution Practices cGDP and other similar standards applicable to the pharmaceutical industry We are frequently audited by regulatory agencies to ensure that our systems and therapies meet the requirements of applicable local laws and codes In addition we routinely carry out self inspection audits together with audits of our suppliers to identify measure control and react to potential issues that may affect the quality and safety of our products We provide appropriate and ongoing education and training to our employees involved in the manufacture testing and distribution of our therapies to ensure they are equipped to perform their duties effectively and in compliance with methods and processes approved by regulatory agencies CSL is committed to continuous evaluation of the benefits and risks of our therapies We maintain a global pharmacovigilance system designed to capture investigate and report any adverse event associated with or thought to be associated with the use of our therapies This system ensures CSL can rapidly evaluate safety reports and provide appropriate safety information to patients healthcare providers and regulators and take prompt action if necessary Safety and the manufacture of plasma therapies Every medicine possesses some level of safety risk For plasma derived therapies the most important safety issue is the potential for contamination with pathogens originating from the plasma used to manufacture these therapies Although the theoretical risk of pathogen transmission can never be zero we use multiple and overlapping safety measures to reduce this risk to as low as is technically feasible Since the introduction of dedicated virus reduction and removal steps and thorough quality assurance measures in plasma fractionation there have been no reports of proven transmission of a pathogen via a plasma derived therapy manufactured by CSL Safety and the manufacture of vaccines CSL operates the largest influenza vaccine manufacturing plant in the southern hemisphere located in Parkville Australia The plant has a manufacturing capacity of up to 80 million doses of influenza vaccine each year produced for markets including Australia US and Europe Each year the World Health Organisation WHO Global Influenza Network provides CSL with influenza virus samples which represent the influenza strains predominating in the southern and northern hemispheres The WHO and local regional authorities then make recommendations for the composition of the vaccine for the southern and northern hemispheres respectively This ensures that the influenza strains in the vaccine match as closely as possible with the viruses that are likely to circulate in the following southern and northern hemisphere winters Our dedicated production plant is maintained at the highest standard and is subject to regular inspections by regulatory authorities including the Australian Therapeutic Goods Administration TGA and the US Food and Drug Administration FDA CSL s influenza vaccine is an inactivated vaccine i e it does not contain live influenza virus The production process involves the use of validated procedures to chemically inactivate the virus The safety and effectiveness of our influenza vaccine has been documented extensively in clinical studies conducted in

    Original URL path: http://www.csl.com.au/corporate-responsibility/safety-quality.htm (2014-01-05)
    Open archived version from archive

  • In the Marketplace
    medicines is an important issue in the pharmaceutical sector especially for patients governments and providers Pricing is one of a number of factors that can affect patient access in developed and developing markets We seek to price our therapies fairly and competitively in all markets and we work with governments patient groups and other healthcare stakeholders to address access issues relevant to our therapy areas In many countries prices for our therapies are negotiated directly with governments or other major payers based on demonstration of cost effectiveness or through a competitive tender process In other countries where our therapies are predominantly supplied via the private market prices are established based on a number of factors including competitive market forces and applicable government controls It is important to recognise that the price a consumer pays for medicines in the private market is also affected by duties and tariffs imposed on imported medicines as well as price mark ups by intermediaries such as wholesalers and pharmacies and in some cases an additional fee by the healthcare provider In all cases we seek to ensure the prices of our medicines reflect their clinical value to patients the community and government in terms of efficacy safety and disease prevention whilst balancing the high risks associated with R D and the need for a fair return on investment Contributing to Public Policy At CSL we believe we can make important contributions to public policy on issues that directly impact our businesses and where we have particular expertise Our public policy initiatives are focused largely in Australia the US and Europe More information on CSL s public policy focus areas can be found in our corporate responsibility reports Political Contributions CSL s Political Contributions Statement requires that any donations supporting the work of party and political candidates or representatives be reasonably balanced among parties candidates or representatives and must be in accordance with applicable local laws and regulations CSL Behring employees in the United States have formed a CSL Behring Employees Political Action Committee PAC This legal entity has its administrative support provided by CSL Behring consistent with US federal law but is managed by an employee PAC member board it is not controlled or managed as part of CSL Behring and the company cannot contribute funds for distribution to political candidates Anti Corruption CSL s Code of Responsible Business Practice CRBP contains a clear policy statement that all our businesses and employees must not directly or indirectly offer pay solicit or accept payments or give or receive personal rewards or inducements in exchange for making business decisions and that our employees and directors must not accept gifts or entertainment where doing so might influence or be perceived to influence objective business judgment The Anti Bribery and Anti Corruption Policy builds on the current statement in the CRBP and supports the considerable amount of work being undertaken in many areas of CSL s operations to ensure that CSL is acting with Integrity one of our core

    Original URL path: http://www.csl.com.au/corporate-responsibility/marketplace.htm (2014-01-05)
    Open archived version from archive

  • Working Environment
    growth and long term success As outlined in the Code of Responsible Business Conduct CSL aims to respect and encourage diversity in all its forms and in particular to promote gender diversity in the workplace In addition CSL s Diversity Policy 0 03Mb sets out in detail our commitment The policy outlines the importance of diversity and inclusiveness to CSL and how as a Company we will incorporate diversity into our business practices Each year CSL develops specific gender diversity objectives which will ensure we continue to build strong and consistent systems and processes to further support a diverse workplace Disclosure and progress towards our objectives are available in our Annual Report online or PDF and Shareholder review CSL met its reporting requirements under the Australian Federal Government s Workplace Gender Equality Act WGEA and submitted its annual public report on 30 May 2013 View CSL s 2013 WGEA report Learning and development CSL provides learning and development opportunities for employees at all levels We aim to continually improve our employees capabilities to help them fulfil their roles safely effectively and consistently This enhances our performance as a company and facilitates employees development as they pursue their career goals and ambitions Reward and recognition Remuneration systems vary between countries but we aim for rewards to be based on local market levels and on job value established through a job evaluation system Performance reviews of all professional specialist administrative and managerial staff are conducted against predetermined performance measures contained in annual work plans Individual and business performance is linked to reward with the proportion of performance related remuneration increasing with seniority Remuneration for managers and executives typically includes a fixed component and a short term cash bonus Packages also may include long term incentives in the form of equity or cash

    Original URL path: http://www.csl.com.au/corporate-responsibility/work-environment.htm (2014-01-05)
    Open archived version from archive

  • The involvement and participation of CSL Limited in the community
    for people with rare and serious conditions we believe that helping our patient communities and advancing knowledge in our therapy areas is part of our corporate responsibility We also recognise that we have a role to play in contributing to humanitarian programs and relief efforts around the world and that closer to home our responsibilities extend to supporting critical needs and sustainable development in our local communities To support our focus areas CSL has developed a global community framework that includes CSL donates 12 000 units of CytoGam for NIH clinical trial Read More Support for Patient Communities Enhancing quality of life for patients in the conditions our therapies treat Improving access to our biological medicines For more information on contributions to Australian Patient Groups click here Support for Biomedical Communities Advancing knowledge in medical and scientific communities Fostering the next generation of medical researchers CSL Florey Medal winner announced Read More Support for Local Communities Supporting community efforts where we live and work Supporting communities in times of emergency CSL donates to disaster relief efforts in Australia New Zealand and Japan Read More In seeking to achieve our community objectives we look for opportunities that utilise our unique capabilities

    Original URL path: http://www.csl.com.au/corporate-responsibility/community.htm (2014-01-05)
    Open archived version from archive

  • CSL Limited's environmental committment
    resources are essential inputs to the production of our life saving therapies Our manufacturing processes and the packaging and transport of our medicines generate greenhouse gas emissions and waste We are committed to minimising these environmental impacts without compromise to the safety quality and affordability of our medicines CSL s commitment to the environment is set by the Board and articulated in our Code of Responsible Business Practice Our Global

    Original URL path: http://www.csl.com.au/corporate-responsibility/environment.htm (2014-01-05)
    Open archived version from archive